位置:首页 > 产品库 > TAK-700 R-form
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
TAK-700 R-form
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
TAK-700 R-form图片
CAS NO:752243-39-3
规格:98%
分子量:307.35
包装与价格:
包装价格(元)
5mg询价
10mg询价
50mg询价
200mg询价

17, 20-lyase inhibitor
CAS:752243-39-3
分子式:C18H17N3O2
分子量:307.35
纯度:98%
存储:Store at -20°C

Background:

TAK-700 R-form is a highly selective inhibitor of 17, 20-lyase with IC50 value of 38nM [1].


TAK-700 is a potent and selective inhibitor of the 17, 20-lyase activity of CYP17A1 which is responsible for androgen biosynthesis. Thus, TAK-700 is selected as a candidate for treatment of prostate cancer through reducing the adrenal androgen production. As an inhibitor of CYP17A1, the selectivity of TAK-700 is important to avoid causing the drug–drug interactions or side effects. TAK-700 shows potent inhibitory activity and high selectivity against 17, 20-lyase over other CYPs including 11-hydroxylase and CYP3A4. The IC50 values for 11-hydroxylase and CYP3A4 are above 1μM and above 10μM, respectively. Moreover, in a monkey model, the administration of TAK-700 is found to significantly reduce serum testosterone and DHEA levels [1].


参考文献:
[1] Kaku T, Hitaka T, Ojida A, et al. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17, 20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorganic & medicinal chemistry, 2011, 19(21): 6383-6399.


 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024